Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial
- PMID: 18207018
- DOI: 10.1016/S0140-6736(08)60134-8
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial
Abstract
Background: Evidence suggests that inflammatory mediators contribute to development and progression of chronic heart failure. We therefore tested the hypothesis that immunomodulation might counteract this pathophysiological mechanism in patients.
Methods: We did a double-blind, placebo-controlled study of a device-based non-specific immunomodulation therapy (IMT) in patients with New York Heart Association (NYHA) functional class II-IV chronic heart failure, left ventricular (LV) systolic dysfunction, and hospitalisation for heart failure or intravenous drug therapy in an outpatient setting within the past 12 months. Patients were randomly assigned to receive IMT (n=1213) or placebo (n=1213) by intragluteal injection on days 1, 2, 14, and every 28 days thereafter. Primary endpoint was the composite of time to death from any cause or first hospitalisation for cardiovascular reasons. The study continued until 828 primary endpoint events had accrued and all study patients had been treated for at least 22 weeks. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00111969.
Findings: During a mean follow-up of 10.2 months, there were 399 primary events in the IMT group and 429 in the placebo group (hazard ratio 0.92; 95% CI 0.80-1.05; p=0.22). In two prespecified subgroups of patients--those with no history of previous myocardial infarction (n=919) and those with NYHA II heart failure (n=689)--IMT was associated with a 26% (0.74; 0.57-0.95; p=0.02) and a 39% (0.61; 95% CI 0.46-0.80; p=0.0003) reduction in the risk of primary endpoint events, respectively.
Interpretation: Non-specific immunomodulation may have a role as a potential treatment for a large segment of the heart failure population, which includes patients without a history of myocardial infarction (irrespective of their functional NYHA class) and patients within NYHA class II.
Comment in
-
Immunosuppression as therapy for congestive heart failure.Lancet. 2008 Jan 19;371(9608):184-6. doi: 10.1016/S0140-6736(08)60115-4. Lancet. 2008. PMID: 18207004 Clinical Trial. No abstract available.
-
Non-specific immunomodulation in chronic heart failure.Lancet. 2008 Jun 21;371(9630):2083; author reply 2084. doi: 10.1016/S0140-6736(08)60914-9. Lancet. 2008. PMID: 18572074 No abstract available.
-
Non-specific immunomodulation in chronic heart failure.Lancet. 2008 Jun 21;371(9630):2083; author reply 2084. doi: 10.1016/S0140-6736(08)60913-7. Lancet. 2008. PMID: 18572075 No abstract available.
-
Immunomodulation through autohemotherapy in chronic heart failure.Forsch Komplementmed. 2008 Aug;15(4):230. Forsch Komplementmed. 2008. PMID: 18795463 No abstract available.
Similar articles
-
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.Lancet. 2008 Oct 4;372(9645):1223-30. doi: 10.1016/S0140-6736(08)61239-8. Epub 2008 Aug 29. Lancet. 2008. PMID: 18757090 Clinical Trial.
-
Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.Lancet. 2016 Jun 11;387(10036):2412-21. doi: 10.1016/S0140-6736(16)30137-4. Epub 2016 Apr 5. Lancet. 2016. PMID: 27059887 Clinical Trial.
-
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.Lancet. 2010 Sep 11;376(9744):886-94. doi: 10.1016/S0140-6736(10)61259-7. Lancet. 2010. PMID: 20801495 Clinical Trial.
-
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial.Lancet. 2021 Sep 11;398(10304):991-1001. doi: 10.1016/S0140-6736(21)01754-2. Epub 2021 Aug 27. Lancet. 2021. PMID: 34461042 Clinical Trial.
-
Remote monitoring of pulmonary artery pressures with CardioMEMS in patients with chronic heart failure and NYHA class III: first experiences in the Netherlands.Neth Heart J. 2018 Feb;26(2):55-57. doi: 10.1007/s12471-017-1054-4. Neth Heart J. 2018. PMID: 29127645 Free PMC article. Review.
Cited by
-
Chinese Society of Cardiology guidelines on the diagnosis and treatment of adult fulminant myocarditis.Sci China Life Sci. 2024 May;67(5):913-939. doi: 10.1007/s11427-023-2421-0. Epub 2024 Feb 7. Sci China Life Sci. 2024. PMID: 38332216 Review.
-
Immunomodulation and immunopharmacology in heart failure.Nat Rev Cardiol. 2024 Feb;21(2):119-149. doi: 10.1038/s41569-023-00919-6. Epub 2023 Sep 14. Nat Rev Cardiol. 2024. PMID: 37709934 Review.
-
Inflammation and Heart Failure: Searching for the Enemy-Reaching the Entelechy.J Cardiovasc Dev Dis. 2023 Jan 4;10(1):19. doi: 10.3390/jcdd10010019. J Cardiovasc Dev Dis. 2023. PMID: 36661914 Free PMC article. Review.
-
Immunomodulatory Cell Therapy Using αGalCer-Pulsed Dendritic Cells Ameliorates Heart Failure in a Murine Dilated Cardiomyopathy Model.Circ Heart Fail. 2022 Dec;15(12):e009366. doi: 10.1161/CIRCHEARTFAILURE.122.009366. Epub 2022 Oct 21. Circ Heart Fail. 2022. PMID: 36268712 Free PMC article.
-
Death without Previous Hospital Readmission in Patients with Heart Failure with Reduced Ejection Fraction-A New Endpoint from Old Clinical Trials.J Clin Med. 2022 Sep 21;11(19):5518. doi: 10.3390/jcm11195518. J Clin Med. 2022. PMID: 36233386 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous